BridgeBio have demonstrably boosted this progress of the innovative treatment for ATTR-CM, utilizing the investigational drug. Initial patient data suggests significant outcomes for those suffering with this severe disease. This emphasis represents BridgeBio's focus to addressing unmet patient demands in this heart disease arena. Attruby: BridgeBi